Elimination of rubella and prevention of congenital rubella infection in Europe has been a high priority for the WHO European Regional Office over the past decade. In 2010 the WHO regional committee for Europe renewed its commitment to the elimination of rubella and prevention of CRS with a new target of 2015. For Central Europe to reach the target of rubella elimination and prevention of CRS by 2015, very high vaccine coverage levels need to be maintained and catch-up campaigns continued to address susceptible groups, in particular women of child-bearing age.
The European Society of Intensive Care Medicine (ESICM) is organising the 24th ESICM LIVES Annual Congress in Berlin on 1-5 October 2011. This congress is one of the major meetings, gathering numerous well-known international experts in the field of intensive care medicine.
Location:Berlin
Organized by:European Society of Intensive Care Medicine
In an editorial in the scientific journal Eurosurveillance, ECDC noted that, based on numerous studies, paediatricians, family practitioners and nurses form the backbone of each national immunisation programme in the EU.
Clostridium difficile infection is the leading cause of healthcare-associated diarrhoea in the developed world and represents a major financial burden for European healthcare systems.
Clostridium difficile infection (CDI) is an intestinal infection usually acquired in hospital settings, after antibiotic treatment. The clinical spectrum of CDI ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis. In the recent years, an increased incidence of CDI has been reported in Europe and worldwide.
Starting 15 September 2011, ECDC will be coordinating the former EUVAC.NET network. It is a surveillance network covering measles, mumps, rubella, congenital rubella, pertussis and varicella EU Member States and three countries of the European Economic Area. Data will be hosted by the European Surveillance System (TESSy) at ECDC.
Patient transfer between hospitals and in particular between countries, is a risk factor for the spread of bacteria that are resistant to last-line antibiotics. More specifically, for highly resistant bacteria, like carbapenamase-producing Enterobacteriaceae (CPE), the risk is heightened when patients are transferred from, or have received previous medical care in areas with high rates of bacterial resistance. These are conclusions from a risk assessment produced by ECDC that evaluated the risk to the citizens of Europe, of the spread of CPE through patient transfer between healthcare facilities, with special emphasis on cross-border transfer.
This review outlines how increasing modalities of travel, such as aeromedical evacuation of civilians and of military personnel, medical tourism and any shared healthcare across countries, are risks for the transmission of multidrug-resistant organisms via the patient, from country to country.
ECDC and WHO Europe jointly release “MESSAGE - MEaSles and rubella Self Assessment GEnerating tool” for public health experts, to facilitate assessment of the progress made towards measles and rubella elimination.
The authors analyzed data on 444 imported cases of methicillin-resistant Staphylococcus aureus (MRSA) in Sweden during the period 2000-2003. The risk for MRSA carriage or infection in returning travellers ranged from 0.1 per million travellers returning from Nordic countries to 59.4 per million travellers returning from North Africa and the Middle East.